WO1998042718A1 - Method for generating saccharide fragments - Google Patents
Method for generating saccharide fragments Download PDFInfo
- Publication number
- WO1998042718A1 WO1998042718A1 PCT/US1998/005889 US9805889W WO9842718A1 WO 1998042718 A1 WO1998042718 A1 WO 1998042718A1 US 9805889 W US9805889 W US 9805889W WO 9842718 A1 WO9842718 A1 WO 9842718A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- polysaccharide
- ozone
- residue
- saccharide
- nucleophile
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/085—Staphylococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/0216—Bacteriodetes, e.g. Bacteroides, Ornithobacter, Porphyromonas
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
- A61K39/092—Streptococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
Definitions
- This invention is in the general field of methods of preparing saccharide fragments.
- Saccharides are important as commodity chemicals and are used often in food and industrial applications. They are also important specialty chemicals in biotechnology, e.g., in the preparation of antibiotics or antibodies, as antigens for vaccines, or as diagnostic reagents .
- Saccharides may be obtained from natural sources or synthesized enzymatically or chemically. Synthesis of saccharides having more than about five monosaccharide units often is difficult, especially if one of the units is sialic acid, which is acid labile. Enzymatic synthesis is limited by the available enzymes and substrates and may be relatively expensive.
- Polysaccharides can be cleaved into smaller molecular weight fragments by acid, base, or enzymatic- catalyzed hydrolysis. Acid catalyzed degradation may cleave polysaccharides nonselectively in both carbohydrate and other functional moieties, yielding inconsistent products or non- functional products.
- sialic acids are found on the carbohydrate moieties of many biologically important polysaccharides and can be determinants of biological functions, including recognition and attachment. They can also be determinants of epitopes for antibody generation and as such should be conserved in attempts to generate saccharide fragments, from polysaccharides. Sialic acids, however, are readily removed by acid.
- Enzymatic hydrolysis of polysaccharides can be highly specific but it is usually limited to applications where an enzyme with the desired specificity is readily available. Some saccharide fragments may alternatively be isolated directly from natural sources, but these naturally occurring shorter polysaccharides typically exist in limited quantity. In some cases, saccharide fragments may be chemically and/or enzymatically synthesized. However, even in those cases the enzymes and substrates necessary to conduct the synthesis may be expensive. In general, the synthesis of saccharide fragments of more than five monosaccharide residues can be extremely difficult. Summary of the Invention The invention is based on the discovery that ozone can be used to cleave polysaccharides to yield useful shorter-length saccharide fragments of a desired length, which generally retain structural features of the polysaccharide .
- the invention features a method for producing a saccharide fragment by oxidizing a larger polysaccharide having at least one covalent bond between a Cl anomeric carbon of an aldose residue and an oxygen atom of a second monosaccharide residue in a /3-D glycosidic linkage.
- the method can also be used when the covalent bond is in the form of an c.-L linkage.
- the 3-D and ⁇ -L linkages will exhibit similar reactivities.
- the Q;-D and /3-L linkages will also exhibit similar reactivities.
- the method comprises protecting free hydroxyl groups on the larger polysaccharide; reacting the larger polysaccharide with ozone to oxidize the Cl anomeric carbon, thus converting the aldose residue into an aldonic acid ester residue; and cleaving the aldonic acid ester residue to form the saccharide fragment .
- the invention features a method of preparing an saccharide fragment by oxidizing a larger polysaccharide having at least one covalent bond between a Cl anomeric carbon of an aldose residue and an oxygen atom of a second monosaccharide residue in an or ⁇ glycosidic linkage (henceforth, referred to as the "one- step" method) .
- the glycosidic linkage can be in any form, e.g., ⁇ -L, ⁇ -D, j ⁇ -L or /3-D.
- the /3-D and ⁇ -L linkages will typically exhibit similar reactivities, and the 0.-D and /3-L linkages will exhibit similar reactivities .
- the one-step method comprises reacting the larger polysaccharide with ozone to cleave a bond linking two monosaccharide subunits in the polysaccharide, resulting in the formation of the saccharide fragment.
- the larger polysaccharide in the methods described herein can be from any source and can contain labile residues, e.g., sialic acid.
- the larger polysaccharide is substantially pure.
- the larger polysaccharide is substantially purified when it is separated from those cellular components which accompany it in its natural state.
- the saccharide fragment may optionally be subsequently purified.
- a purified saccharide fragment is meant a saccharide fragment separated from the starting polysaccharide.
- the polysaccharide may be from a bacterial pathogen, e.g., a group B Streptococcus capsular polysaccharide, such as GBS type I, II, III, IV, V, VI, VII, and VIII; the O-antigen of a lipopolysaccharide; a capsular polysaccharide of Staphylococcus aureus, e.g., the Staphylococcus aureus type 5 or type 8 antigens; the capsular polysaccharide of Streptococcus pneumonia ; and the capsular polysaccharide of Bacteroides fragilis .
- a group B Streptococcus capsular polysaccharide such as GBS type I, II, III, IV, V, VI, VII, and VIII
- the O-antigen of a lipopolysaccharide e.g., a capsular polysaccharide of Staphylococcus aureus, e.g., the Staphy
- the ozone can be added in solution, generated in- situ, or be delivered from an external source, e.g, bubbled in.
- the aldonic acid ester intermediate can be cleaved by a nucleophile, e.g., a hydroxyl ion, an amine, a thiol , or a carbanion.
- a nucleophile e.g., a hydroxyl ion, an amine, a thiol , or a carbanion.
- the aldonic acid ester intermediate may alternatively be cleaved by heating or hydrolysis .
- the invention also includes a method for producing antibodies using saccharide fragments produced by ozonolysis.
- the saccharide fragments can be conjugated to a carrier to create an immunogen, after which the immunogen is injected into a suitable host. Any recognized host is suitable, e.g., rabbit, rat, mouse, goat. Either polyclonal or monoclonal antibodies can be generated.
- the invention has many advantages.
- the methods enable degradation of any polysaccharide containing a glycosidic linkage.
- the one-step procedure allows ozonolysis to take place in an aqueous solution and without the need for pretreating the starting polysaccharide.
- the one-step procedure can be used to depolymerize polysaccharides containing any glycosidic linkage.
- saccharide fragments with the same repeating unit structure can be recovered from abundant, naturally occurring polysaccharides.
- Saccharide fragments produced by this method can be easily modified and linked to other molecules (e.g., protein carriers) . This can make them useful in drug and vaccine design.
- the saccharide fragments may also be tagged with chromophores , biotins, peptides, and lipids and thus have diverse potential applications.
- saccharide fragment is any complex carbohydrate which is formed according to the invention from a starting material which is a "starting polysaccharide".
- starting polysaccharide any complex carbohydrate which is formed according to the invention from a starting material which is a "starting polysaccharide”.
- the size of the saccharide fragment will be a function of various factors, such as the desire for a small molecule that is more conveniently adapted to the end use (e.g., solubilized or reacted with labels), consistent with the need to conserve configuration or properties (e.g., immunological properties) of the larger starting material .
- the polysaccharide starting material will have more than 10 saccharide units, and it will be of a size dictated by its natural source and techniques for recovering it from that source .
- the resulting saccharide fragment cleavage product will have more than 1 unit, and typically will be smaller than 100 units.
- the saccharide fragments produced by the invention may in some cases be much longer than 100 units.
- oligosaccharide appears herein, it is understood that the term is synonymous with "saccharide fragment”.
- Fig. 1 is a diagram showing the repeating unit structure of GBS (Group B streptococcal) capsular polysaccharides .
- Fig. 2 is a graph showing the elution profile following liquid chromatography of saccharide fragments generated from type II GBS polysaccharide after treatment with ozone.
- Fig. 3A-D are the *H NMR spectra of type II GBS native polysaccharide and the saccharides of peaks 3 to 1 of Fig. 2, respectively.
- Fig. 4 is a graph showing the elution profile of saccharide fragments generated from type VIII GBS polysaccharide after treatment with ozone for the indicated amounts of time.
- Fig. 5 is the 1 H NMR spectrum of pooled 7 Kda saccharide fragments generated from type VIII GBS polysaccharide after treatment with ozone.
- Fig. 6 is a graph showing the elution profile of saccharide fragments generated from type III GBS capsular polysaccharide after treatment with ozone.
- Fig. 7A-7C are the X H NMR spectra of type III GBS native polysaccharides (A) , and ozonolysis-generated saccharide fragments of three (B) and two (C) repeating units.
- Fig. 8A-8D are graphs showing the elution profiles of the saccharide fragments generated from type III GBS polysaccharide following treatment with ozone for 150, 195, 270, and 355 minutes, respectively.
- Fig. 9A-9B are graphs showing the repeating unit structure of polysaccharide A of Bacteroides fragilis (9A) , and the elution profile following liquid chromatography of the saccharide fragments generated from polysaccharide A of Bacteroides fragilis (9B) .
- Fig. 10 is a graph showing the molecular weight of saccharide fragments after treatment of a starting type III GBS polysaccharide with ozone for the indicated lengths of time.
- Fig. 11 is the NMR spectrum of type III GBS native polysaccharides following ozonolysis in NaHC0 3 buffer.
- the invention provides new methods for cleaving polysaccharides using ozonolysis.
- ozonolysis is carried out in three steps: 1) hydroxyl groups on the polysaccharide are protected; 2) ozone is applied to the protected polysaccharide to form a partially oxidized intermediate containing an aldonic acid ester; and 3) the aldonic acid ester intermediate is deprotected and hydrolyzed, thereby cleaving the starting polysaccharide into saccharide fragments.
- ozonolysis is carried out in one step: ozone is applied directly to a polysaccharide, which can contain saccharide subunits joined in either a or ⁇ linkages, in an aqueous solution.
- a polysaccharide which can contain saccharide subunits joined in either a or ⁇ linkages, in an aqueous solution.
- ozonolysis may generate an ester or a lactone as described above.
- Any polysaccharide is generally a suitable starting material for the ozonolysis methods.
- Polysaccharides can be purchased commercially or isolated from natural sources by standard methods. For example, polysaccharides can be isolated from bacterial species by methods described by Wessels et al . , J. Biol . Chem.
- This method can be used to selectively depolymerize polysaccharides containing a /3-D or c-L glycosidic linkage.
- the first step of the method protects the free hydroxyl groups of the polysaccharide from subsequent treatment with ozone.
- peracetylation is generally preferred, although other methods such as persilylation and permethylation are also suitable.
- Peracetylation is usually accomplished by treating polysaccharides with acetic anhydride and pyridine; however, acetic anhydride/potassium acetate or acetate anhydride/sodium acetate and the like can also be used as acetylation reagents .
- a cosolvent such as formamide may be added.
- the reaction time can be shortened by increasing the temperature. For example, the reaction takes place either overnight (in 12-24 hours) at room temperature, or in 2 hours at 70°C.
- the excess reagents and solvents are removed using procedures known in the art.
- the reaction mixture can be dialyzed against distilled water, after which the water is removed by lyophilization or evaporated under nitrogen or on a rotary evaporator.
- the solvent can be directly removed using a rotary evaporator. Direct removal typically requires heating or the addition of ethanol to speed the evaporation of pyridine and formamide.
- the protected polysaccharide is dissolved in ethyl acetate, acetic anhydride/potassium acetate, or another ozone- inert solvent such as dichloromethane or tetrahydrofuran.
- the solution is sonicated for a few minutes to dissolve the polysaccharide, after which ozone is added at room temperature.
- a condensation device can be used during the ozone application step.
- the application of ozone to the protected polysaccharide results in the formation of an aldonic acid ester intermediate.
- Various methods of applying the ozone may be used.
- ozone can be delivered from an external ozone generator (More-ZonlO, More Production, Taiwan) , which creates ozone electronically from oxygen or air. Other ozone application methods may also be used. After ozone treatment, the solvent is evaporated on a rotary evaporator.
- an external ozone generator Moore-ZonlO, More Production, Taiwan
- Other ozone application methods may also be used.
- the solvent is evaporated on a rotary evaporator.
- the aldonic ester linkages in the polysaccharide can be hydrolyzed with a base such as 0.1 N NaOH at room temperature for 30 minutes, which simultaneously removes the protecting group.
- the nascent oligomers can alternatively be liberated, and the termini simultaneously functionalized, with another nucleophile known to cleave ester bonds.
- Appropriate nucleophiles include (but are not limited to) alkoxides, phenoxides, carbanions, thiols, and hydrazines .
- the use of an ⁇ ., ⁇ - diamine, for example, leads to an amide linkage of the saccharides to one end of the amine, with the free amino group available for coupling to a carrier or support matrix.
- the aldonic esters may be converted to lactones by simple heating, and the acetyl protecting groups may then be removed in a separate subsequent step.
- degradation of the polysaccharide is accomplished in one step by treating the polysaccharide solution with ozone.
- the polysaccharide substrates are dissolved in any suitable aqueous solvent or buffer solution, e.g., water.
- the reaction is preferably carried out in a basic buffer (e.g., phosphate buffered saline, or sodium bicarbonate) to prevent the loss of acid-sensitive groups.
- Acid formed during the ozonolysis reaction may also be neutralized with a base such as alkali, alkali carbonates, bicarbonates, hydroxides, or other inorganic or organic bases.
- Polysaccharides containing either a or ⁇ linkages, including ⁇ -L, ⁇ -D, /3-L or /3-D linkages, are suitable starting products for the one-step ozonolysis method.
- the polysaccharide contains a /3-D or ⁇ -L linkage, it forms a partially oxidized intermediate containing an aldonic acid ester, which forms a lactone and automatically cleaves the polysaccharide.
- Ozone treatment will preferentially affect the /3-D or ⁇ -L linkages; thus, in relatively brief exposures to ozone, polysaccharides containing /3-D or ⁇ .-L linkages can be preferentially depolymerized at these sites.
- the products resulting from the ozonolysis methods are saccharide fragments terminating with a carboxylate group.
- the carboxylate group can be activated with carbodiimides that function as zero-length cross-linking agents and couple the saccharides to amine-containing molecules .
- Saccharide fragments that contain one or more diol function groups may be selectively oxidized with sodium metaperiodate to create aldehyde groups.
- sialic acid can easily be oxidized by sodium periodate to create a free aldehyde group at the C8 position.
- Such saccharide fragments may then be coupled to molecules containing amine moieties, such as proteins, or to a bifunctional molecule that serves as a spacer and can be further coupled to another molecule.
- the ozonolysis-mediated cleavage is highly selective in that ozone reacts selectively at these linkages; however, the cleavage site is generally random among all the same /3-D glycosidic linkages within a polysaccharide.
- the size distribution of saccharides may be controlled by controlling ozonolysis conditions, including the concentration of the polysaccharide, the reaction time, the rate of ozone passing through the reaction mixture, and the total amount of ozone consumed. For example, longer reaction times and consumption of more ozone result in smaller saccharides.
- Controlled cleavage of the polysaccharide thus results in a mixture of saccharides with a desired, narrow range of sizes which retain the repeating-unit structures of the parent polysaccharide.
- the products of the ozonolysis reaction can be separated by techniques well known in the art, e.g., gel- filtration, size-exclusion, or ion-exchange column chromatography.
- the eluent can be a suitable buffer, such as PBS, TRIS, or distilled water. Fractions are monitored by a refractive index detector or are assayed for carbohydrate contents. Fractions representing different-sized saccharides are pooled and analyzed by spectroscopic methods, typically NMR spectroscopy .
- the sizes of the resulting saccharide fragments are determined either by mass spectrometry (e.g., electrospray) or by measurement of their elution volume and calculation from the calibration curve of the column. Maintenance of polysaccharide function can be verified by an appropriate assay (e.g., an ELISA) .
- polysaccharides suitable for use in the invention include bacterial capsular polysaccharides and lipopolysaccharides, e.g., those from the pathogenic bacteria group B Streptococcus, B . fragilis, S . aureus, and S . pneumoniae .
- Protective polysaccharides associated with these bacteria contain labile sialic acid or pyruvyl (carboxyethylidene) residues that are critical to protective epitopes .
- saccharide fragments generated from these polysaccharides by ozonolysis can be used as diagnostic reagents, therapeutic reagents, or as reagents for the preparation of vaccines.
- fragments of the outer polysaccharide coats of the organisms can be incorporated into a molecular matrix or attached to a carrier.
- Group B Streptococcus capsular polysaccharides were isolated and purified as described by Wessels et al . , J. Biol. Chem. 266:6714 (1991). Preparation of polysaccharide A of Bacteroides fragilis was as described by Tzianabos et al . , J. Biol. Chem. 267:18230 (1992), and the preparation of the capsular polysaccharide of Staphylococcus aureus type 5 was as described by Lee et al . , Infect. Immun. 61: 1853 (1993). Desialyated GBS has a structure identical to the polysaccharide of Streptococcus penu oniae type 14.
- the dried, oxidized material was mixed with 5 ml of 0. IN NaOH at room temperature for 2 hours and then neutralized with dilute acetic acid or hydrochloric acid.
- the oxidized product was treated with 5 ml of allylamine at room temperature for 30 min. The excess allylamine was evaporated under a stream of nitrogen in a hood.
- the saccharide mixture was separated with an FPLC system (Pharmacia) using a Superdex 75 or Superdex 30 column by eluting with 0.3 m PBS buffer with 0.025% azide at pH 7.2. Fractions were monitored by a refractive index detector. Those in desired size ranges were pooled and analyzed by spectroscopic methods. The columns were calibrated with dextran standards, and the molecular weights of saccharide fragments were obtained from column calibration curves.
- NMR analyses were performed on a Varian VXR500 spectrometer (Palo Alto, CA) or a Bruker AMX 500 with a proton resonance frequency of 500 MHz. 1 H spectra were recorded at 70 °C in D 2 0. Proton chemical shifts were referenced relative to water resonance calibrated at 4.290 ppm at 70 °C, 4.632 ppm at 37 °C, and 4.755 ppm at 25°C.
- Example 1 Generation of saccharide fragments from type II GBS polysaccharides using the three-step ozonolysis procedure
- Type II GBS polysaccharide (Fig. 1) was prepared as described and treated with ozone for five hours. The saccharide fragments were separated on a Superdex 75 column (HiLoadTM16/60 , prep grade, Pharmacia), which has a size separation range of 0.5-30 kDa . The fractions were monitored by a differential refractometer (WATERSR401TM, Millipore Corp., Bedford, MA).
- peaks 1 and 2 had average molecular weights of 2.7 kDa and 4.3 kDa, respectively.
- the native type II GBS polysaccharide has a heptasaccharide repeating unit of 1.3 kDa, these peaks corresponded to two and three repeating units, respectively.
- peak 3 and the higher molecular weight peaks saccharide fragments with four and more repeating units elute.
- the H NMR spectra of the type II GBS native polysaccharide and the saccharide fragments of peaks 1-3 are shown in Fig. 3.
- the NMR structure of the native polysaccharide reveals a heptasaccharide repeating unit, as indicated by the six anomeric protons between 4.4 ppm and 5.2 ppm from the hexose residues, along with a sialic acid residue, as revealed by its ⁇ -resonance at 2.85 ppm and 1.86 ppm (Fig. 3A) .
- Fig. 3B shows that the majority of peak 3 is a saccharide fragment of four repeating units with an NMR spectrum identical to that of the native polysaccharide.
- Figs. 3C and 3D demonstrate that peaks 2 and 1 correspond to saccharides of three and two repeating units, respectively.
- the 11 anomeric signals at 4.90 ppm (2), 4.84 ppm (2), 4.76 ppm, 4.66 ppm, 4.62 ppm, and 4.50 ppm (4) correspond to the 11 hexose residues, along with two sialic acid residues and a terminal aldonic residue, of the two repeating units.
- the sialic acid residue is retained in all fragments, as indicated by its X H signals at 2.85 ppm and 1.86 ppm in all the spectra.
- Example 2 Generation of saccharide fragments from type VIII GBS polysaccharides using the three-step ozonolysis procedure following ozonolysis for varying amounts of time
- the doublet at 1.4 ppm is due to the 6-deoxy protons of the rhamnose residue.
- the signals at 2.9 ppm and 1.9 ppm are due to the 3-H of the sialic acid residue.
- the spectrum of the pooled 7-kDa fractions is identical to that of the native polysaccharide, indicating that the saccharide retained the parental repeat structure.
- Example 3 Generation of saccharide fragments from type III GBS polysaccharides using the three-step ozonolysis procedure
- the LC profile of saccharide fragments generated upon treatment of type III GBS polysaccharides with ozone is shown in Fig. 6. Saccharide fragments were separated on a Superdex 75 column and eluted with 0.3m M PBS. Peaks 1 and 2 correspond to saccharide fragments containing two and three copies of the type III repeats, respectively.
- Fig. 7 shows the 1 H NMR spectra of the native type III GBS polysaccharide and of peaks 2 and 1 of Fig. 6, respectively.
- the native polysaccharide (Fig. 7A) has a pentasaccharide repeating unit, as revealed by the four anomeric protons (between 4.4 ppm and 4.8 ppm) from the four hexose residues, and a sialic acid residue, as revealed by its 3-H resonance at 2.77 ppm and 1.80 ppm.
- Peak 2 (Fig. 7B) is mainly a saccharide of three repeating units. Its NMR spectrum is identical to that of the native polysaccharide. Peak 1 (Fig. 7A) has a pentasaccharide repeating unit, as revealed by the four anomeric protons (between 4.4 ppm and 4.8 ppm) from the four hexose residues, and a sialic acid residue, as revealed by its 3-H resonance at 2.77 pp
- 7C corresponds to a saccharide of two repeating units (10 residues) .
- Fig. 8 shows the LC profile after ozonolysis for 150, 195, 270, and 355 minutes, respectively. At each time point, the saccharides generated were of uniform size and fell within narrow size distributions.
- the sizes of the saccharide fragment products for each duration of ozonolysis were determined with a
- Superose 12 column which has a size separation range of 1-300 kDa.
- the average sizes of the saccharides at the time points shown in Figs. 8A through 8D corresponded to 42, 23, 21, and 20 kDa, respectively.
- the average sizes of the saccharides obtained were 16, 14, and 5 kDa, respectively (data not shown) .
- Example 4 Generation of saccharide fragments from polysaccharide A of Bacteroides fragilis using the three- step ozonolysis procedure
- the repeating unit of the polysaccharide A from Bacteroides fragilis has the structure shown in Fig. 9A.
- Fig. 9B shows the LC profile of the saccharides generated upon ozonolysis treatment of the Bacteroides fragilis polysaccharide A using a Superdex75 column.
- the average molecular weights for peaks 1-3 were 2.1, 4.3, and 6.6 kDa, respectively.
- a saccharide fragment from a type III GBS polysaccharide (5 mg) obtained after ozonolysis was dissolved in 0.375 ml of water and oxidized with 0.125 ml of 0.01 M sodium metaperiodate at room temperature in the dark for 90 minutes (Wessels et al . , J. Clin. Invest. 86:1428 (1990)) .
- the mixture was then dialyzed against water and lyophilized.
- the oxidized saccharide sample was combined with 4 mg of tetanus toxoid, and the combination was dissolved in 0.3 ml of 0.1 M NaHC0 3 (pH 8.2), with 20 mg of sodium cyanoborohydride added. The mixture was incubated at 37 °C overnight.
- the conjugate vaccine product was purified on a S-300 column (Pharmacia) .
- Example 6 Generation of saccharide fragments from ⁇ - containing polysaccharides and a-containing polysaccharides using the one-step ozonolysis procedure
- polysaccharides of GBS type III, type 14 S . pneumoniae, or dextran were used as the starting material .
- GBS type III polysaccharide 8.3 mg was dissolved in 1 ml of water and bubbled with ozone for 47 minutes. During this time the pH of the solution was monitored. The reaction mixture became slightly acidic after 20 minutes of ozonolysis, at which time a few drops of a 0.033 M NaHC0 3 solution was added until the solution returned to neutral pH. At various time intervals, a 30 ⁇ l aliquot of the reaction mixture was taken and screened on a Superose 12 column to check the size of the products .
- the product was purified on a P2 Biogel column (Biorad, Hercules, CA) and eluted with water on a FPLC system. One major peak was obtained.
- the collected fractions from the FPLC column were then pooled, lyophilized, and subjected to 1 H NMR spectroscopy.
- the 1 H NMR spectrum is shown in Fig. 11.
- the spectra was identical to that of the starting polysaccharide, thus demonstrating that the saccharide fragment product has the same subunit structure as the starting polysaccharide.
- the acid-labile sialic residue of the type III GBS was retained as shown by the characteristic H-3 resonances at 2.8 and 1.8 ppm.
- type III GBS polysaccharide and type 14 S . pneumoniae polysaccharide demonstrate that polysaccharides containing ⁇ linkages can be cleaved to saccharide fragments while retaining the subunit linkages.
- the one-step ozonolysis procedure was carried out using dextran as the starting polysaccharide.
- Dextran is a polysaccharide composed exclusively of the D-glucopyranosyl units connected via an o.-(l,6) linkage.
Abstract
Description
Claims
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP54328198A JP2001519817A (en) | 1997-03-26 | 1998-03-26 | Sugar fragment generation method |
EP98914310A EP0977764A4 (en) | 1997-03-26 | 1998-03-26 | Method for generating saccharide fragments |
CA002284606A CA2284606A1 (en) | 1997-03-26 | 1998-03-26 | Method for generating saccharide fragments |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US4241697P | 1997-03-26 | 1997-03-26 | |
US60/042,416 | 1997-03-26 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1998042718A1 true WO1998042718A1 (en) | 1998-10-01 |
Family
ID=21921821
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1998/005889 WO1998042718A1 (en) | 1997-03-26 | 1998-03-26 | Method for generating saccharide fragments |
Country Status (5)
Country | Link |
---|---|
US (2) | US6027733A (en) |
EP (1) | EP0977764A4 (en) |
JP (1) | JP2001519817A (en) |
CA (1) | CA2284606A1 (en) |
WO (1) | WO1998042718A1 (en) |
Cited By (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003080678A1 (en) * | 2002-03-26 | 2003-10-02 | Chiron Srl | Modified saccharides having improved stability in water |
EP2731617A4 (en) * | 2011-07-12 | 2015-07-01 | Brigham & Womens Hospital | Lipid-containing psa compositions, methods of isolation and methods of use thereof |
EP2942396A1 (en) | 2014-05-07 | 2015-11-11 | Novartis AG | Polysaccharides produced by CPSC mutants |
US10772918B2 (en) | 2013-05-10 | 2020-09-15 | California Institute Of Technology | Probiotic prevention and treatment of colon cancer |
US10857177B2 (en) | 2015-08-19 | 2020-12-08 | President And Fellows Of Harvard College | Lipidated PSA compositions and methods |
US11103566B2 (en) | 2010-05-20 | 2021-08-31 | California Institute Of Technology | Antigen specific Tregs and related compositions, methods and systems |
US11331335B2 (en) | 2015-06-10 | 2022-05-17 | California Institute Of Technology | Sepsis treatment and related compositions methods and systems |
US11419887B2 (en) | 2010-04-07 | 2022-08-23 | California Institute Of Technology | Vehicle for delivering a compound to a mucous membrane and related compositions, methods and systems |
US11491181B2 (en) | 2016-07-15 | 2022-11-08 | President And Fellows Of Harvard College | Glycolipid compositions and methods of use |
US11622973B2 (en) | 2007-11-09 | 2023-04-11 | California Institute Of Technology | Immunomodulating compounds and related compositions and methods |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0977764A4 (en) * | 1997-03-26 | 2001-04-11 | Brigham & Womens Hospital | Method for generating saccharide fragments |
US6692739B1 (en) | 1998-08-31 | 2004-02-17 | Inhibitex, Inc. | Staphylococcal immunotherapeutics via donor selection and donor stimulation |
US6492897B1 (en) | 2000-08-04 | 2002-12-10 | Richard A. Mowery, Jr. | System for coupling wireless signals to and from a power transmission line communication system |
CA2461906A1 (en) * | 2001-09-27 | 2003-04-10 | Heppe Gmbh Biotechnologische Systeme Und Materialien | Method and device for producing modified polysaccharide-based oligomers |
US20040096461A1 (en) * | 2002-07-30 | 2004-05-20 | Baxter Healthcare Corporation | Chimeric multivalent polysaccharide conjugate vaccines |
GB0502095D0 (en) | 2005-02-01 | 2005-03-09 | Chiron Srl | Conjugation of streptococcal capsular saccharides |
GB0502096D0 (en) | 2005-02-01 | 2005-03-09 | Chiron Srl | Purification of streptococcal capsular polysaccharide |
US20090136547A1 (en) * | 2005-08-24 | 2009-05-28 | Novartis Vaccines And Diagnostics Srl | Zwitterionization of capsular saccharides |
GB0605757D0 (en) | 2006-03-22 | 2006-05-03 | Chiron Srl | Separation of conjugated and unconjugated components |
US9358302B2 (en) | 2009-03-23 | 2016-06-07 | The Brigham And Women's Hospital, Inc. | Glycoconjugate vaccines |
CN102596254B (en) * | 2009-09-30 | 2016-10-19 | 诺华股份有限公司 | Staphylococcus aureus 5 type and the coupling of CP8 |
BR122019005883A8 (en) | 2009-10-30 | 2022-10-04 | Novartis Ag | METHOD FOR CAPSULAR POLYSACCHARIDE RELEASE, STAPHYLOCOCCUS AUREUS TYPE 5 AND TYPE 8 CAPSULAR SACCHARIDE PURIFICATION PROCESS AND COMPOSITION |
GB201101665D0 (en) | 2011-01-31 | 2011-03-16 | Novartis Ag | Immunogenic compositions |
US9855325B2 (en) | 2012-10-03 | 2018-01-02 | Glaxosmithkline Biologicals Sa | Immunogenic composition |
WO2017175082A1 (en) | 2016-04-05 | 2017-10-12 | Gsk Vaccines S.R.L. | Immunogenic compositions |
MA47175A (en) * | 2016-12-30 | 2019-11-06 | Shanghai Green Valley Pharmaceutical Co Ltd | PROCESS FOR DEGRADATION OF A POLYSACCHARIDE USING OZONE |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3723506A (en) * | 1971-08-11 | 1973-03-27 | Univ Sherbrooke | Oxidation of sugars |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE2917104A1 (en) * | 1979-04-27 | 1980-11-06 | Hoechst Ag | METHOD FOR REDUCING THE VISCOSITY OF CELLULOSE ETHERS BY OZONE AND ITS USE |
US4356170A (en) * | 1981-05-27 | 1982-10-26 | Canadian Patents & Development Ltd. | Immunogenic polysaccharide-protein conjugates |
DE3840044A1 (en) * | 1988-11-27 | 1990-06-07 | Behringwerke Ag | GLYCOSPHINGOLIPIDS WITH A COUPLABLE GROUP IN THE SPHINGOID PART, THEIR PRODUCTION AND USE |
FI895708A0 (en) * | 1989-02-10 | 1989-11-29 | Alko Ab Oy | VATTENLOESLIG SOENDERDELNINGSPRODUKT. |
CA2059693C (en) * | 1991-01-28 | 2003-08-19 | Peter J. Kniskern | Polysaccharide antigens from streptococcus pneumoniae |
US5565204A (en) * | 1994-08-24 | 1996-10-15 | American Cyanamid Company | Pneumococcal polysaccharide-recombinant pneumolysin conjugate vaccines for immunization against pneumococcal infections |
EP0977764A4 (en) * | 1997-03-26 | 2001-04-11 | Brigham & Womens Hospital | Method for generating saccharide fragments |
US5929049A (en) * | 1997-08-08 | 1999-07-27 | Dade Behring Marburg Gmbh | Polysaccharide conjugates of biomolecules |
-
1998
- 1998-03-26 EP EP98914310A patent/EP0977764A4/en not_active Withdrawn
- 1998-03-26 CA CA002284606A patent/CA2284606A1/en not_active Abandoned
- 1998-03-26 WO PCT/US1998/005889 patent/WO1998042718A1/en not_active Application Discontinuation
- 1998-03-26 JP JP54328198A patent/JP2001519817A/en active Pending
- 1998-03-26 US US09/048,705 patent/US6027733A/en not_active Expired - Lifetime
-
2000
- 2000-01-21 US US09/488,938 patent/US6274144B1/en not_active Expired - Lifetime
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3723506A (en) * | 1971-08-11 | 1973-03-27 | Univ Sherbrooke | Oxidation of sugars |
Non-Patent Citations (1)
Title |
---|
See also references of EP0977764A4 * |
Cited By (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003080678A1 (en) * | 2002-03-26 | 2003-10-02 | Chiron Srl | Modified saccharides having improved stability in water |
EP1777236A1 (en) * | 2002-03-26 | 2007-04-25 | Novartis Vaccines and Diagnostics S.r.l. | Modified saccharides having improved stability in water |
US11622973B2 (en) | 2007-11-09 | 2023-04-11 | California Institute Of Technology | Immunomodulating compounds and related compositions and methods |
US11419887B2 (en) | 2010-04-07 | 2022-08-23 | California Institute Of Technology | Vehicle for delivering a compound to a mucous membrane and related compositions, methods and systems |
US11103566B2 (en) | 2010-05-20 | 2021-08-31 | California Institute Of Technology | Antigen specific Tregs and related compositions, methods and systems |
EP2731617A4 (en) * | 2011-07-12 | 2015-07-01 | Brigham & Womens Hospital | Lipid-containing psa compositions, methods of isolation and methods of use thereof |
US9539281B2 (en) | 2011-07-12 | 2017-01-10 | The Brigham And Women's Hospital, Inc. | Lipid-containing PSA compositions, methods of isolation and methods of use thereof |
US10772918B2 (en) | 2013-05-10 | 2020-09-15 | California Institute Of Technology | Probiotic prevention and treatment of colon cancer |
EP2942396A1 (en) | 2014-05-07 | 2015-11-11 | Novartis AG | Polysaccharides produced by CPSC mutants |
US11331335B2 (en) | 2015-06-10 | 2022-05-17 | California Institute Of Technology | Sepsis treatment and related compositions methods and systems |
US10857177B2 (en) | 2015-08-19 | 2020-12-08 | President And Fellows Of Harvard College | Lipidated PSA compositions and methods |
US11491181B2 (en) | 2016-07-15 | 2022-11-08 | President And Fellows Of Harvard College | Glycolipid compositions and methods of use |
Also Published As
Publication number | Publication date |
---|---|
EP0977764A1 (en) | 2000-02-09 |
JP2001519817A (en) | 2001-10-23 |
EP0977764A4 (en) | 2001-04-11 |
CA2284606A1 (en) | 1998-10-01 |
US6274144B1 (en) | 2001-08-14 |
US6027733A (en) | 2000-02-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6027733A (en) | Method for generating saccharide fragments | |
EP1051506B2 (en) | Procedures for the extraction and isolation of bacterial capsular polysaccharides for use as vaccines or linked to proteins as conjugates vaccines | |
Pozsgay | Synthesis of glycoconjugate vaccines against Shigella dysenteriae type 1 | |
Wang et al. | Ozonolytic depolymerization of polysaccharides in aqueous solution | |
EP1109576B1 (en) | Immunogenic beta-propionamido-linked polysaccharide protein conjugate useful as a vaccine produced using an n-acryloylated polysaccharide | |
CA2941174C (en) | Novel polysaccharide immunogens from clostridium difficile | |
WO2007084856A2 (en) | Method for purifying polysaccharides | |
Vann et al. | Structure and serological specificity of the K13-antigenic polysaccharide (K13 antigen) of urinary tract-infective Escherichia coli | |
KR19990022747A (en) | Antigenic Group VIII Streptococcus Type II and Type III Polysaccharides Having 2,5-Anhydro-D-Mannose Terminal Structures and Combination Vaccines thereof | |
Visansirikul et al. | Staphylococcus aureus capsular polysaccharides: a structural and synthetic perspective | |
US9777076B2 (en) | Saccharides and uses thereof | |
Kogan et al. | Structural elucidation of the novel type VII group B Streptococcus capsular polysaccharide by high resolution NMR spectroscopy | |
Xiong et al. | Synthesis and immunological studies of oligosaccharides that consist of the repeating unit of Streptococcus pneumoniae serotype 3 capsular polysaccharide | |
Pazur et al. | Determination of the sugar-sequences and the glycosidic-bond arrangements of immunogenic heteroglycans | |
JP4958368B2 (en) | Cross-linked hyaluronic acid | |
Lorentzen et al. | Synthesis of an Elicitor‐Active Heptaglucan Saccharide for Investigation of Defense Mechanisms of Plants | |
Pozsgay et al. | Towards an oligosaccharide-based glycoconjugate vaccine against Shigella dysenteriae type 1 | |
Lohmann | Structural diversity and functional versatility of polysaccharides | |
CN100491403C (en) | Modified saccharides having improved stability in water | |
Khan et al. | Oligosaccharides, polysaccharides and related compounds |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): CA JP |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
ENP | Entry into the national phase |
Ref document number: 2284606 Country of ref document: CA Ref country code: CA Ref document number: 2284606 Kind code of ref document: A Format of ref document f/p: F |
|
ENP | Entry into the national phase |
Ref country code: JP Ref document number: 1998 543281 Kind code of ref document: A Format of ref document f/p: F |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1998914310 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1998914310 Country of ref document: EP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1998914310 Country of ref document: EP |